Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Monoferric vs Iron Sucrose in Iron Deficiency Anemia (FERWON-IDA)
NCT02940886Phase 3Completed
- Sponsor
- Pharmacosmos
- Start
- Nov 2016
- Primary completion
- Mar 2018
- Modality
- Inorganic Nanoparticles, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of ferric derisomaltose in iron deficiency anemia (IDA), sponsored by Pharmacosmos. Primary endpoints: Change in Hemoglobin From Baseline to Week 8 and Incidence of Protocol-defined Serious or Severe Hypersensitivity Reactions at 8 weeks. Started Nov 2016; status: completed.
02
Drugs
ferric derisomaltose
03
Conditions
iron deficiency anemia (IDA)
Beyond the preview
Go deeper on NCT02940886.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02940886.